BR112023010885A2 - Terapia de combinação de anti-cd19 - Google Patents
Terapia de combinação de anti-cd19Info
- Publication number
- BR112023010885A2 BR112023010885A2 BR112023010885A BR112023010885A BR112023010885A2 BR 112023010885 A2 BR112023010885 A2 BR 112023010885A2 BR 112023010885 A BR112023010885 A BR 112023010885A BR 112023010885 A BR112023010885 A BR 112023010885A BR 112023010885 A2 BR112023010885 A2 BR 112023010885A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- combination therapy
- lenalidomide
- chop
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20211862 | 2020-12-04 | ||
| EP21158806 | 2021-02-23 | ||
| EP21163696 | 2021-03-19 | ||
| EP21172671 | 2021-05-07 | ||
| EP21177336 | 2021-06-02 | ||
| EP21205447 | 2021-10-29 | ||
| PCT/EP2021/084133 WO2022117799A2 (en) | 2020-12-04 | 2021-12-03 | Anti-cd19 combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023010885A2 true BR112023010885A2 (pt) | 2023-10-03 |
Family
ID=78821967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023010885A BR112023010885A2 (pt) | 2020-12-04 | 2021-12-03 | Terapia de combinação de anti-cd19 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220184208A1 (https=) |
| EP (1) | EP4255480A2 (https=) |
| JP (1) | JP2023551559A (https=) |
| KR (1) | KR20230131464A (https=) |
| AU (1) | AU2021391623A1 (https=) |
| BR (1) | BR112023010885A2 (https=) |
| CA (1) | CA3204063A1 (https=) |
| CL (1) | CL2023001581A1 (https=) |
| IL (1) | IL303384A (https=) |
| MX (1) | MX2023006538A (https=) |
| TW (1) | TW202237184A (https=) |
| WO (1) | WO2022117799A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| CA3255552A1 (en) * | 2021-12-22 | 2023-06-29 | Incyte Corporation | TREATMENT PARADIGM FOR ANTI-CD19 ANTIBODY THERAPY |
| AU2023285109A1 (en) * | 2022-06-10 | 2024-12-12 | Incyte Corporation | Combination therapy comprising sirp alpha fusion protein and anti-cd19 antibody for treatment of cancer |
| KR102835682B1 (ko) * | 2022-06-16 | 2025-07-22 | 애브비 바이오테라퓨틱스 인크. | 항-cd19 항체-약물 접합체 |
| WO2024037594A1 (en) * | 2022-08-19 | 2024-02-22 | Beijing Innocare Pharma Tech Co., Ltd. | Combination treatment with orelabrutinib and tafasitamab |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| CN103459425B (zh) * | 2010-10-27 | 2015-11-25 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的组合物 |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| FI3916392T3 (fi) * | 2016-05-30 | 2024-06-03 | Incyte Corp | Menetelmiä cd19-vasta-ainehoidon terapeuttisen hyödyn ennakoimiseksi potilailla |
| US20200230254A1 (en) * | 2016-07-22 | 2020-07-23 | Seattle Genetics, Inc. | Combination therapy using a cd19-adc and rchp |
| CN118593691A (zh) * | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
-
2021
- 2021-12-03 WO PCT/EP2021/084133 patent/WO2022117799A2/en not_active Ceased
- 2021-12-03 IL IL303384A patent/IL303384A/en unknown
- 2021-12-03 US US17/541,627 patent/US20220184208A1/en active Pending
- 2021-12-03 BR BR112023010885A patent/BR112023010885A2/pt unknown
- 2021-12-03 AU AU2021391623A patent/AU2021391623A1/en active Pending
- 2021-12-03 TW TW110145312A patent/TW202237184A/zh unknown
- 2021-12-03 CA CA3204063A patent/CA3204063A1/en active Pending
- 2021-12-03 EP EP21819888.5A patent/EP4255480A2/en active Pending
- 2021-12-03 JP JP2023533838A patent/JP2023551559A/ja active Pending
- 2021-12-03 KR KR1020237022358A patent/KR20230131464A/ko active Pending
- 2021-12-03 MX MX2023006538A patent/MX2023006538A/es unknown
-
2023
- 2023-06-01 CL CL2023001581A patent/CL2023001581A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3204063A1 (en) | 2022-06-09 |
| WO2022117799A2 (en) | 2022-06-09 |
| IL303384A (en) | 2023-08-01 |
| TW202237184A (zh) | 2022-10-01 |
| AU2021391623A9 (en) | 2024-07-11 |
| WO2022117799A3 (en) | 2022-07-14 |
| CL2023001581A1 (es) | 2023-12-15 |
| EP4255480A2 (en) | 2023-10-11 |
| MX2023006538A (es) | 2023-08-08 |
| JP2023551559A (ja) | 2023-12-08 |
| AU2021391623A1 (en) | 2023-06-29 |
| US20220184208A1 (en) | 2022-06-16 |
| KR20230131464A (ko) | 2023-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023010885A2 (pt) | Terapia de combinação de anti-cd19 | |
| PH12021550553A1 (en) | Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell | |
| BR112018074406A2 (pt) | métodos para o tratamento de malignidades de células b utilizando terapia celular adotiva | |
| BR112021025537A2 (pt) | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica | |
| MX2022013163A (es) | Anticuerpo contra nectin-4 y aplicacion del mismo. | |
| CY1121331T1 (el) | Αγωγη αιματολογικων κακοηθειων me αντισωμα anti-cxcr4 | |
| EP4200445A4 (en) | DETECTION OF NON-HODGKIN'S LYMPHOMA | |
| BR112021022815A2 (pt) | Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina | |
| CY1125148T1 (el) | Θεραπεια συνδυασμου με αντι-cd19 αντισωμα και αναλογο πουρινης | |
| ATE530577T1 (de) | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren | |
| BR112018074619A2 (pt) | uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer | |
| BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
| WO2014143807A3 (en) | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders | |
| CY1110759T1 (el) | Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| CY1126559T1 (el) | Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης | |
| CY1124648T1 (el) | Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου | |
| WO2015116729A3 (en) | Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders | |
| ZA202100296B (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
| BR112022012310A2 (pt) | Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica | |
| BR112023023622A2 (pt) | Métodos para tratar linfoma difuso, kits, imunoconjugados, polatuzumabe vedotina e imunoconjugado para uso | |
| WO2019138005A3 (en) | Novel combination and use of antibodies | |
| BR112022017162A2 (pt) | Terapia anti-cd19 em combinação com lenalidomida para o tratamento de leucemia ou linfoma | |
| EA202191170A1 (ru) | Комбинированная терапия для лечения гематологических заболеваний | |
| MX392561B (es) | Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: INCYTE CORPORATION (US) |